Mirati Therapeutics Inc
Change company Symbol lookup
Select an option...
MRTX Mirati Therapeutics Inc
SIRC Solar Integrated Roofing Corp
CHSTY China High Speed Transmission Equipment Group Co Ltd
TTMZF Datable Technology Corp
WVFC W V S Financial Corp
WHLM Wilhelmina International Inc
SON Sonoco Products Co
VIRX Viracta Therapeutics Inc
PFS Provident Financial Services Inc
LPLA LPL Financial Holdings Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Mirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. The Company is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.

Premarket

Last Trade
Delayed
$70.06
-1.46 (-2.04%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$71.52
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
222

10-day average volume:
2,168,695
222

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Barclays PLC with Losses of $100,000 to Contact the Firm

4:52 pm ET September 24, 2022 (BusinessWire) Print

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Barclays PLC ("Barclays" or "the Company") (NYSE: BCS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's American Depositary Receipts ("ADRs") between February 18, 2021 and March 25, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before November 22, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Barclays' wholly owned subsidiary, Barclays Bank PLC ("BBPLC"), sold $17.64 billion in unregistered securities above the maximum amount allowed by its two shelf registration statements. The Company suffered from material weaknesses in its internal controls over financial reporting. The Company failed to disclose BBPLC's over-issuance, or that the subsidiary was in violation of SEC regulations and/or securities laws, creating liabilities for the parent Company. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Barclays, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220924005009/en/

SOURCE: The Schall Law Firm

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com 
Office: 310-301-3335
info@schallfirm.com
comtex tracking

COMTEX_415206092/1006/2022-09-24T16:52:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.